LONDON, Jan. 18, 2018 /PRNewswire/ -- Smith & Nephew
(NYSE: SNN; LSE: SN), the global medical technology business, today
announces results showing a near 75% decrease in readmission rates
for joint arthroplasties (TJA) conducted under its Episode of Care
Assurance Program (eCAP).
Working with Provider PPI, eCAP combines Smith & Nephew's
leading hip and knee implants with its PICO™ Negative Pressure
Wound Therapy and ACTICOAT™ Flex 7 Antimicrobial Barrier Dressings.
These products are applied post-surgery; PICO may help protect the
incision by reducing seroma and hematoma fluid collections,
reducing edema and lateral tension and improving
perfusion.1-5 ACTICOAT Flex 7, which contains
Nanocrystalline Silver, provides an effective barrier to microbial
contamination to help deter surgical site
infections.6
Over the past year over 1,000 TJAs have been conducted under the
eCAP program with only two readmissions, a readmission rate of only
0.20% as compared to published rates of 5.3% or
more.7
"As healthcare systems move from fee for service to pay for
value, healthcare providers are increasingly responsible for the
episode of care for the patient," said Glenn Warner, President Smith & Nephew US.
"eCAP can help enable providers to reduce costly readmissions after
TJA by adding class-leading wound care products to help manage
surgical incisions. We are proud to support our customers with
innovative programs that deliver improved care in a large-scale,
real-world setting."
Smith & Nephew worked with Provider PPI, a group purchasing
organization, to implement this program at Provider PPI's client
facilities in late 2016 with positive results, and is now serving
16 facilities across the US.
"Adding PICO and Acticoat products from Smith & Nephew to
our TJA cases has been a great win for our health system clients
and their patients," said Paul
Gallagher, Vice President, Provider PPI. "I am extremely
pleased to see our readmission rate drop to nearly zero. In Smith
& Nephew we've worked with a comprehensive product solutions
partner that's willing to stand behind its product portfolio."
References
- Lumb H. Bacterial barrier testing (wet-wet) of PICO™ dressing
with a 7 day test duration against S. marcescens.
- Wilkes RP, et al. Closed incision management with negative
pressure wound therapy (CIM): Biomechanics. Surg Innov 2011.
- Karlakki S, et al. Negative Pressure Wound Therapy for
management of the surgical incision in Orthopedic surgery. A review
of evidence and mechanisms for an emerging indication. Bone Joint
Res 2013; 2: 276-284.
- Canonico S, et al. Therapeutic possibilities with portable
NPWT. Initial multidisciplinary observations with the negative
pressure device. Acta Vulnol 2012; 10: 57-66.
- Selvaggi F, et al. New advances in Negative Pressure Wound
Therapy (NPWT) for surgical wounds of patients affected with
Crohn's Disease. Surg Tech Int 2014; XXIV: 83- 89.
- Burrell et al. Efficacy of Silver-Coated Dressing as Bacterial
Barriers in a Rodent Burn Sepsis Model, WOUNDS 1999;
11(4):64-71.
- Unplanned Readmission After Total Joint Arthroplasty: Rates,
Reasons, And Risk Factors - The Journal Of Bone & Joint Surgery
- jbjs.org - Volume 95-A - Number 20 October
16, 2013.
For detailed product information, including indications for use,
contraindications, effects, precautions and warnings, please
consult each product's Instructions for Use (IFU) prior to
use.
About Smith & Nephew
Smith & Nephew is a
global medical technology business dedicated to helping healthcare
professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports
Medicine and Trauma & Extremities, Smith & Nephew has
around 15,000 employees and a presence in more than 100 countries.
Annual sales in 2016 were almost $4.7
billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN)
Forward-looking Statements
This document may contain
forward-looking statements that may or may not prove accurate. For
example, statements regarding expected revenue growth and trading
margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target",
"consider" and similar expressions are generally intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that could cause actual results to differ materially from
what is expressed or implied by the statements.
For Smith & Nephew, these factors include: economic and
financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or
other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™Trademark of Smith & Nephew. Certain marks
registered US Patent and Trademark Office.
View original content with
multimedia:http://www.prnewswire.com/news-releases/smith--nephews-episode-of-care-assurance-program-ecap-reduces-hospital-readmission-following-total-joint-replacement-surgery-300584409.html
SOURCE Smith & Nephew